Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clinic proceedings Silber, M. H., Buchfuhrer, M. J., Earley, C. J., Koo, B. B., Manconi, M., Winkelman, J. W., Scientific and Medical Advisory Board of the Restless Legs Syndrome Foundation, Earley, C. J., Becker, P., Berkowski, J. A., Buchfuhrer, M. J., Clemens, S., Connor, J. R., Ferre, S., Hensley, J. G., Jones, B. C., Karroum, E. G., Koo, B., Manconi, M., Ondo, W., Richards, K., Sharon, D., Silber, M. H., Trotti, L. M., Uhl, G., Walters, A. S., Winkelman, J. W. 2021; 96 (7): 1921-1937

Abstract

Restless legs syndrome (RLS) is a common disorder. The population prevalence is 1.5% to 2.7% in a subgroup of patients having more severe RLS with symptoms occurring 2 or more times a week and causing at least moderate distress. It is important for primary care physicians to be familiar with the disorder and its management. Much has changed in the management of RLS since our previous revised algorithm was published in 2013. This updated algorithm was written by members of the Scientific and Medical Advisory Board of the RLS Foundation based on scientific evidence and expert opinion. A literature search was performed using PubMed identifying all articles on RLS from 2012 to 2020. The management of RLS is considered under the following headings: General Considerations; Intermittent RLS; Chronic Persistent RLS; Refractory RLS; Special Circumstances; and Alternative, Investigative, and Potential Future Therapies. Nonpharmacologic approaches, including mental alerting activities, avoidance of substances or medications that may exacerbate RLS, and oral and intravenous iron supplementation, are outlined. The choice of an alpha2-delta ligand as first-line therapy for chronic persistent RLS with dopamine agonists as a second-line option is explained. We discuss the available drugs, the factors determining which to use, and their adverse effects. We define refractory RLS and describe management approaches, including combination therapy and the use of high-potency opioids. Treatment of RLS in pregnancy and childhood is discussed.

View details for DOI 10.1016/j.mayocp.2020.12.026

View details for PubMedID 34218864